Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinoline derivatives, pharmaceutically acceptable salts thereof and methods of use thereof

A pharmacy and drug technology, applied to quinoline derivatives, can solve problems such as weak affinity

Active Publication Date: 2021-08-24
VTV THERAPEUTICS LLC +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The PDE4 isozyme family has high affinity for cyclic AMP but weak affinity for cyclic GMP

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinoline derivatives, pharmaceutically acceptable salts thereof and methods of use thereof
  • Quinoline derivatives, pharmaceutically acceptable salts thereof and methods of use thereof
  • Quinoline derivatives, pharmaceutically acceptable salts thereof and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0083] Synthesis of compound I and its HCl salt

[0084] step 1:

[0085] To a 40 mL reaction vial was added ethyl 4-chloro-8-methoxyquinoline-3-carboxylate (1.25 g, 4.7 mmol), m-chloroaniline (0.69 g, 5.4 mmol, 1.15 equiv), 1-butanol (10 mL) and acetic acid (0.3 mL). The mixture was stirred at 95°C for 5 hours, IPC LCMS indicated the reaction was complete. 1-Butanol was removed in vacuo, and the mixture was diluted with ethyl acetate (75 mL). The organic layer was washed with saturated aqueous sodium bicarbonate (25 mL), and concentrated to dryness. The residue was purified by flash column chromatography eluting with DCM / ethyl acetate (1:0 to 1:1) to give the ester intermediate 4-(3-chloroanilino)-8-methoxy-quinone Ethyl pheno-3-carboxylate (1.05 g). Yield 62%. LCMS m / e 357.1(M+1) + ; 1 H NMR, 300MHz (CDCl 3 )δ1.45(t,3H),4.08(s,3H),4.44(q,2H),6.84(br d,1H),6.99(t,1H),7.04(dd,1H),7.05(d, 1H), 7.16(t,1H), 7.20s,1H), 7.22(dd,1H), 9.29(s,1H), 10.25(s,1H)ppm.

[0086] S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to compound trans-4-[1-(3-chlorophenyl)-7-methoxy-2,4-dioxo-pyrimido[5,4-c]quinoline-3-yl] Cyclohexanecarboxylic acid, its pharmaceutically acceptable salts and their use as therapeutic agents, including in the treatment of inflammatory disorders.

Description

technical field [0001] The present invention relates to the compound trans-4-[1-(3-chlorophenyl)-7-methoxy-2,4-dioxo-pyrimido[5,4-c]quinolin-3-yl] Cyclohexanecarboxylic acid, its pharmaceutically acceptable salts and their use as therapeutic agents for the treatment of TNF-alpha or PDE4 mediated diseases. Background technique [0002] Tumor necrosis factor-α (TNF-α), also known as TNF, DIF, TNF-α, TNFA and TNFSF2, is a cell-associated cytokine that is processed from a 26kd precursor form to a 17kd soluble form. TNF-α has been shown to be a master regulator of inflammation, fever and acute phase responses in humans and animals, similar to those observed during acute infection and shock. Excess TNF-α has been shown to be lethal. There is currently substantial evidence that blocking the action of TNF-alpha, either by using soluble TNF receptors or by using specific neutralizing antibodies, is beneficial in a variety of conditions, including autoimmune diseases such as rheumat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61K31/519A61P11/00A61P11/06A61P11/02A61P37/08A61P29/00A61P19/02A61P17/00A61P17/06A61P1/04A61P13/12A61P25/28A61P25/24A61P1/00A61P9/10A61P25/00A61P1/16A61P21/04A61P1/12A61P27/02A61P31/06A61P9/04A61P35/00A61P37/02A61P7/06A61P25/16A61P31/12A61P7/02A61P19/10A61P17/16A61P1/02A61P3/10
CPCC07D471/04A61P11/00A61P11/06A61P11/02A61P37/08A61P29/00A61P19/02A61P17/00A61P17/06A61P1/04A61P13/12A61P25/28A61P25/24A61P1/00A61P9/10A61P25/00A61P1/16A61P21/04A61P1/12A61P27/02A61P31/06A61P9/04A61P35/00A61P37/02A61P7/06A61P25/16A61P31/12A61P7/02A61P19/10A61P17/16A61P1/02A61P3/10Y02A50/30A61K31/4738
Inventor B.加达姆
Owner VTV THERAPEUTICS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com